Elan Targeted In Off-Label Marketing Probe

Law360, New York (March 5, 2007, 12:00 AM EST) -- Irish pharmaceutical company Elan Corp. is facing a kickback probe from the U.S. Department of Justice and the Department of Health over the promotion of epilepsy drug Zonegran for off-label uses.

Zonegran, also known as zonisamide, is approved in the United States for the treatment of partial epileptic seizures in adults.

The drug was marketed by Elan from 2000 to 2004, when it sold its interests in Zonegran to Eisai Co. Ltd. for approximately $130 million.

Researchers are investigating its use in treating tremors for Parkinson’s...
To view the full article, register now.